Building together a better future

News

1
2
3
4
5
6
7
8

Cellectis S.A. to Explore Possible Initial Public Offering of Calyxt, Inc.

Learn more

Cellectis to Present at the 2017 Annual Conference of the American Association for Cancer Research

Learn more

Servier and Pfizer announce FDA clearance of IND application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia

Learn more

Five Additional Leading Physicians to Join Cellectis Clinical Advisory Board

Learn more

Cellectis to Present at the LEERINK Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at 1:30pm ET in New York

Learn more

FDA Grants Cellectis IND Approval to Proceed with the Clinical Development of UCART123, the First Gene Edited Off-the-Shelf CAR T-Cell Product Candidate developed in the U.S.

Learn more

Four Prominent Physicians to Join Cellectis Clinical Advisory Board

Learn more

Cellectis Studies Safety in New CAR Architecture Controlling CAR T-Cell Functions

Learn more

Cellectis Submits IND Application for UCART123, an Allogeneic Gene Edited CAR T-Cell Product Candidate, in AML and BPDCN

Learn more

Cellectis to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 8:00am PT

Learn more

Cellectis Submits IND Application for UCART123, an Allogeneic Gene Edited CAR T-Cell Product Candidate, in AML and BPDCN

Learn more

Cellectis to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 8:00am PT

Learn more

Cellectis Announces Conference Call To Discuss Recent Recombinant DNA Advisory Committee (RAC) Meeting

Learn more

Cellectis Announces Recombinant DNA Advisory Committee’s (RAC) Unanimous Approval of UCART123 Phase 1 Study Protocols in AML and BPDCN

Learn more

Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2016

Learn more

Cellectis to Participate in Oppenheimer Life Sciences Summit, NY & in Piper Jaffray 28th Annual Health Care Conference, NY

Learn more

Manufacturing Adoptive Immunotherapies

How are UCART product candidates made?

Read the leaflet

Share price

€ 21.10 04/21/2017 - 17:35:21 ALCLS (ALCLS)

$ 22.65 04/21/2017 - 16:00:00 CLLS

learn more

SUBMIT

question
or request

Click here

SIGN UP

to receive our publications

Click here